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Abstract
Background: Chloroquine resistance (CQR) phenotype in Plasmodium falciparum is associated with mutations in
pfcrt and pfmdr-1 genes. Mutations at amino acid position 72-76 of pfcrt gene, here defined as pfcrt haplotype are
associated with the geographic origin of chloroquine resistant parasite. Here, mutations at 72-76 and codon 220 of
pfcrt gene and N86Y pfmdr-1 mutation were studied in blood samples collected across 11 field sites, inclusive of
high and low P. falciparum prevalent areas in India. Any probable correlation between these mutations and clinical
outcome of CQ treatment was also investigated.
Methods: Finger pricked blood spotted on Whatman No.3 papers were collected from falciparum malaria patients
of high and low P. falciparum prevalent areas. For pfcrt haplotype investigation, the parasite DNA was extracted
from blood samples and used for PCR amplification, followed by partial sequencing of the pfcrt gene. For pfmdr-1
N86Y mutation, the PCR product was subjected to restriction digestion with AflIII endonuclease enzyme.
Results: In 240 P. falciparum isolates with reported in vivo CQ therapeutic efficacy, the analysis of mutations in pfcrt
gene shows that mutant SVMNT-S (67.50%) and CVIET-S (23.75%) occurred irrespective of clinical outcome and wild
type CVMNK-A (7.91%) occurred only in adequate clinical and parasitological response samples. Of 287 P. falciparum
isolates, SVMNTS 192 (66.89%) prevailed in all study sites and showed almost monomorphic existence (98.42% isolates)
in low P. falciparum prevalent areas. However, CVIETS-S (19.51%) and CVMNK-A (11.84%) occurrence was limited to high
P. falciparum prevalent areas. Investigation of pfmdr-1 N86Y mutation shows no correlation with clinical outcomes. The
wild type N86 was prevalent in all the low P. falciparum prevalent areas (94.48%). However, mutant N86Y was
comparably higher in numbers at the high P. falciparum prevalent areas (42.76%).
Conclusions: The wild type pfcrt gene is linked to chloroquine sensitivity; however, presence of mutation cannot
explain the therapeutic efficacy of CQ in the current scenario of chloroquine resistance. The monomorphic
existence of mutant SVMNT haplotype, infer inbreeding and faster spread of CQR parasite in areas with higher
P. vivax prevalance and chloroquine exposure, whereas, diversity is maintained in pfcrt gene at high P. falciparum
prevalent areas.
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Widespread Plasmodium falciparum chloroquine resis-
tance (CQR) continues to pose a great challenge to
malaria control efforts [1]. CQR is associated with single
nucleotide polymorphisms (SNPs), which cause non-
synonymous amino acid substitutions in the P. falciparum
chloroquine resistance transporter (pfcrt) gene. As a result,
the pfcrt gene is commonly used in epidemiological studies
to characterize chloroquine treatment failure and ulti-
mately monitor the emergence of drug resistance within
endemic regions [2]. The replacement of a lysine (K) by a
threonine (T) at codon 76 of the pfcrt gene seems to be a
hallmark of CQR worldwide; both in vitro and in vivo tests
suggest its use as an epidemiological tool for large scale
studies of CQR in the field [3,4]. Twenty additional SNP’s
have been identified in the pfcrt gene from CQR field iso-
lates, which may be due to selective pressure driving the
population structure [5]. Two major haplotypes defined by
specific mutations at amino acid positions 72-76 of pfcrt,
CVIET and SVMNT, are associated with the geographic
origin of CQR [6]. The CVIET haplotype is predominantly
found in Southeast Asia and Africa, whereas the SVMNT
haplotype is characteristic of South America, Papua New
Guinea (PNG) [7], and the Philippines [8]. However, the
CVIET haplotype has been observed in South America
[9-11] and SVMNT haplotype in Southeast Asia [12].
Most African isolates share the CVIET haplotype of
Southeast Asia, and it is hypothesized that this haplotype
was imported through the Indian subcontinent [13].
Chloroquine-sensitive (CQS) strains are characterized by
the CVMNK haplotype, irrespective of geographic origin.
In India, the first P. falciparum chloroquine resistant case
was reported in 1973 [14] and subsequently swept
throughout the country [15]. The most prevalent pfcrt
haplotype identified in India is SVMNT, although CVIET
has also been observed [16-18]. A recent study reported
that the SVMNT haplotype found in central India is clo-
sely related to the SVMNT genotype found in PNG [19],
but it has yet to be determined if these two haplotypes
have independent origins.
Similarly, SNPs in the P. falciparum multidrug resis-
tance-1 (pfmdr-1) gene have been associated with reduced
susceptibility to chloroquine treatment. Specifically, a SNP
causing a nonsynonymous amino acid substitution at
amino acid position 86, replaces the wild type asparagine
(N) with a resistant tyrosine (Y) [20-22]. Most studies,
including those performed in India, observe weak associa-
tions between pfmdr-1 mutations and parasite that are
CQR [4,16,17,23].
Historically, P. vivax has been the principal malaria spe-
cies in India; however, during the past two decades the
incidence of P. falciparum has more than doubled; this
has been attributed to a rise in chloroquine resistance
across India [15]. Chloroquine resistance may have been
exacerbated by misdiagnosis and consequently improper
anti-malarial drug treatment, as chloroquine (CQ) is the
first-line drug for vivax malaria in India [24]. Given that
P. falciparum causes more severe and complicated forms
of malaria, a resurgence of this parasite is alarming. Lim-
ited data is available on the distribution of P. falciparum
resistant genotypes in regions typically dominated by
P. vivax. Also, there is an overall lack of information on
how these genetic haplotypes correlate with clinical resis-
tance to CQ in India. Due to this, it is difficult to track
CQR throughout India and nearly impossible to predict
potential outbreaks of resistant parasites. This is a serious
cause for concern, especially in regions of India where
vivax malaria is the dominant species. During this study,
CQR was monitored on molecular level by investigating
the distribution of pfcrt haplotypes (concatenating muta-
tions at codons 72-76 and codon 220) and the pfmdr-1
N86Y mutation across 11 field sites. Both high and low
P. falciparum endemic sites in India were included to
account for the impact of transmission intensity on the
appearance of resistance and sensitive phenotypes with
respect to these markers. Widespread parasite resistance
to chloroquine was observed in India, while sensitive para-
sites appeared mostly in high P. falciparum endemic sites,
like Chhattisgarh, Jharkhand, and Orissa [15].
Methods
Selection of isolates
The samples included in this study were collected from
two independent studies: (i) 240 samples from a CQ thera-
peutic efficacy trial occurring in eight different field sites
of varying P. falciparum prevalence (sites 1-8, below) and
(ii) 47 samples collected by random malaria surveys in 3
additional sites (site 9-11, below). All of the samples were
collected between 2002-2006. In the CQ therapeutic effi-
cacy trial, patients were classified according to World
Health Organization guidelines as: adequate clinical and
parasitological response (ACPR), early treatment failure
(ETF), and late treatment failure (LTF). All information
about this clinical trial has been described elsewhere
[25-27]. The Ethics Committee of National Institute of
Malaria Research (NIMR) approved this study protocol.
All individuals or the parents/guardians of children gave
written informed consent before inclusion in the study.
Study sites
The proportion of P. vivax and P. falciparum varies in dif-
ferent parts of India. The study sites below represent the
variable profiles of malaria transmission in India (Figure 1),
classified into two groups according to Pf a l c i p a r u mtrans-
mission. First, regions with high P. falciparum transmission:
the Northeastern (Assam, W. Bengal), Eastern (Orissa,
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garh) regions of India. Second, regions with low P. falci-
parum transmission: North Central (UttarPradesh),
Western (Rajasthan, Gujarat, Goa), and Southern (Tamil
Nadu) part of India. These regions are described in detail
below.
1. Orissa, Eastern coastal state: Sundergarh district
(latitudes 21°35’N to 22°35’N, and longitude 83°32’Et o
85°22’E) presents ideal ecological conditions for malaria,
with undulating uplands intersected by forested hills,
rocky streams, and paddy fields. This state contributes
23% to the country’s malaria burden. In general, malaria
endemicity ranges from meso- to hyperendemic malaria,
with annual transmission. Sample collection from this
field site occurred during year 2003. During this time,
P. falciparum was the dominant infecting species,
accounting for approximately 94% (n = 56331) of all
recorded malaria infections.
2. Assam, North-Eastern state: Kamrup district (lati-
tudes 25°46’N to 26°49’N, and longitudes 90°48’Et o9 1 °
50’E) is predominantly forest (1166.94 sq km of the dis-
trict). Assam is near (80-100 km) the international bor-
ders of Myanmar, China and shares international
borders with Bangladesh and Bhutan. The district had
moderate and perennial malaria transmission with
approximately 83% (n = 4645) due to P. falciparum of
all malaria cases recorded in year 2002.
3. Jharkhand, Eastern state: Simdega district (latitudes
20°10’Nt o2 0 ° 4 0 ’N, and longitudes 84°E to 84°34’E) cov-
ered with forested area (1194.50 sq km of the district) is
highly endemic for P. falciparum malaria. A total of 97%
(n = 8,618) of the recorded malaria cases in year 2006
were P. falciparum infected, and it represented approxi-
mately 7% of the country’st o t a lm a l a r i ab u r d e ni ns a m e
year.
4. West Bengal, Eastern state: Darjleeng district (lati-
tude 27°42’N and longitude 88°16’E) is covered with
forested hills, as it is located in the foothills of Himalayas.
The district shares an international border with Nepal,
Bangladesh, and Bhutan. Malaria transmission in the dis-
trict is moderate, with seasonal malaria transmission of
malaria. During the sample collection year 2003, P. falci-
parum comprised approximately 60% (n = 2157) of
malaria infections in this region.
5. Goa, Western coast: Panaji (latitudes 15°N and
longitude 73°E), in the North Goa district, is an urban
JHARKHAND (N=34)
P.f%=97, API= 16.36
CVMNKA ; 20.58%
SVMNTS  ; 17.64%
CVIETS    ; 58.82%
CVMDTS ; 2.94%
pfmdr-1 N86 ; 55.88%
MAHARASTRA (N=14)
P.f%=62, API=7.79
CVMNKA ; 35.72% 
SVMNTS  ; 64.28%
pfmdr-1 N86 ; 100%
ORISSA (N=54)
P.f%=94, API= 31.83, 
CVMNKA ; 20.37 %
SVMNTS ; 46.29% 
CVIETS ; 31.48% 
SVMNTA ; 1.85%
pfmdr-1 N86 ; 51.85%
ASSAM (N=26)
P.f%=83, API= 2.26
SVMNTS ; 42.30%
CVIETS   ; 57.69%
pfmdr-1 N86 ; 24%
TAMIL NADU (N=25)
P.f%=9, API= 6.63
SVMNTS ; 100%
pfmdr-1 N86 ; 96%
GOA (N=26)
P.f%=20-25, API= 8.92
SVMNTS ; 96.15%
CVIETS    ; 3.85%
pfmdr-1 N86 ; 100%
W. BENGAL (N=16)
P.f%=60, API= 2.01
SVMNTS ; 75% 
CVIETS   ; 25%
pfmdr-1 N86 ; 75%
CHHATISGARH (N=16)
P.f%=95, API= 28.54, 
CVMNKA ; 68.75%
SVMNTS ; 25%
CVMNKS ; 6.25% 
pfmdr-1 N86 ; 81.25%
GUJARAT (N=33)
P.f%=7, API=10.03
SVMNTS ; 100%
pfmdr-1 N86 ; 96.96%
RAJASTHAN (N=26)
P.f%=19, API=2.33
CVMNKA ; 3.85%
SVMNTS ; 96.25%
pfmdr-1 N86 ; 80.76%
U. PRADESH (N=17)
P.f%=8.58, API=0.59
SVMNTS ; 100%
pfmdr-1 N86 ; 100%
Figure 1 Distribution of pfcrt haplotype and wild type pfmdr-1 N86. Distribution of pfcrt haplotype and wild type pfmdr-1 N86, in different
geographic areas of India with varied P.falciparum prevalence. P.f : P.falciparum, API: Annual parasite index, N: no. of isolates, pfcrt haplotype are
CVMNKA,SVMNTS,CVIETS.
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much ongoing construction work, which provides a
higher rate of human migration and promotes a niche for
malaria transmission. P. vivax is the predominant malaria
species in Panaji, however the percentage of P. falci-
parum malaria has increased up to 20-25% in last 5
years. The field site record indicates that P. falciparum
comprised 20.5% (n = 1298) of all the malaria cases in
the year 2004.
6. Gujarat, Western state: Anand district (latitude 22°
57’N and longitude 72°93’E) is a rural area with plains.
Anand is prone to malaria epidemics, but typically has low
and seasonal transmission. P. vivax is the predominant
malaria species in this district; only 7% (n = 1358) of the
malaria was attributed to P. falciparum infection in the
year 2005..
7. Rajasthan, Western state: Udaipur district (latitude
24°35’N and longitude 73°41’E) is located in the plains
and has low and seasonal transmission. In year 2003,
P. falciparum contributed only 19% (n = 1151) of the
total malaria burden within this district.
8. Tamil Nadu, Southern coastal state: Rameswarum
Island (latitude 9°22’N and longitude 78°52’E) in Rama-
nathapuram district of Tamil Nadu is a pilgrimage site,
where human travel from various parts of country is a
daily routine. Rameswarum Island is an endemic region
for P. vivax malaria and has perennial transmission.
Samples were collected in year2004, and only 9% (n =
359) of the malaria burden was attributed to P. falci-
parum in same year.
9. Chhattisgarh, Central state: Kanker district, (lati-
tudes 20°6’N to 20°24’N, and longitudes 80°48’E to 81°
48’E) have small hilly pockets throughout the district.
Malaria endemicity is high, with annual transmission. In
sample collection year 2006, P. falciparum malaria
accounted for approximately 95% (n = 20573) of the
total malaria burden in the same region.
10. Maharastra, Western state: Gadchiroli district (lati-
tude 20°6’N and longitude 80°E) in the state of Maharastra
is covered with dense forest and hills. The forest covers
approximately 75.9% of the geographical areas of the dis-
trict. Malaria endemicity is high, with annual transmission.
In year 2002, P. falciparum accounted for approximately
62% (n = 4732) of the malaria burden in the district.
11. Uttar Pradesh, North Central State: Gautam Budh
Nagar district (latitude 28°34’Na n dl o n g i t u d e7 7 ° 3 3 ’E) is
an industrial area, located in the plains, heavily populated
with migrant labourers from across the country. Malaria
endemicity is low and seasonal, with P. vivax accounting
for the highest burden of malaria within this region. In
year 2002, P. falciparum only accounted for approximately
9% (n = 17) of the total malaria cases recorded in the
district.
Genomic DNA isolation and PCR amplification
Genomic DNA was extracted from blood spots collected
on Whatman No.3 filter paper, using a QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany).
pfcrt and pfmdr-1 genes were amplified from extracted
DNA by nested PCR assays. Primary and nested PCR
assays were performed in a 20 μl volume reaction with
0.75 U of Taq DNA polymerase, 2.5 mM MgCl2, 0.25 mM
dNTP’s and 0.01 mM of primers. The primary PCR pro-
duct was diluted 1:10 times, before performing the nested
reaction. All the primer sequence and PCR conditions are
described in Table 1. For pfmdr-1 N86Y mutation, the
nested PCR product was subjected to restriction digestion
at 37°C with 5U of AflIII (MBI, Fermentas) endonuclease
for 6 h.
Sequence analysis
Final pfcrt PCR product was purified with a column based
gel extraction kit (MDI, India), and then was subjected to
automated sequencing. The sequences obtained were
aligned using MegAlign module of Lasergene Version 5
(DNASTAR, Inc., USA).
Statistical analysis
A c
2 test or Fisher’s exact test (GraphPad Software, Inc)
was used to compare the frequency of pfcrt haplotypes
between groups of high and low P. falciparum endemicity.
Results
T h ed a t ai nt h i ss t u d yh a sb e e na n a l y s e di nt w ow a y s :( i )
regional distribution of mutations (sites 1-11) and (ii)
mutation analysis in relation to in vivo CQ efficacy clinical
trial (sites 1-8).
Regional distribution of pfcrt and pfmdr-1 mutations
After the pfcrt gene was sequenced for all 287 isolates from
11 different study sites, the mutations were assembled into
a single haplotype by concatenating the amino acids
located in positions 72-76 and position 220. The distribu-
tion of pfcrt haplotypes is presented in Table 2. The
mutant SVMNT-S haplotype was the most prevalent hap-
lotype within all sites, comprising 192 (66.89%) of all the
isolates observed in this study. Not surprisingly, there was
less diversity in the low transmission regions, compared to
the high transmission regions; however, this limited diver-
sity was dominated by the mutant SVMNT-S haplotype
(125 of 127 isolates or 98.42%). There were three major
haplotypes found within regions of high transmission
across India: (i) the mutant haplotype SVMNT-S com-
prises 67 (41.87%) of the total; (ii) the mutant haplotype
CVIET-S comprises 56 (35.00%) of the total; and (iii) the
wild type haplotype CVMNK-A comprises 34 (21.25%) of
the total. Compared with the low transmission regions,
Mallick et al. Malaria Journal 2012, 11:16
http://www.malariajournal.com/content/11/1/16
Page 4 of 10both the CVIET-S mutant and the wild type CVMNK-A
haplotype occurred at significantly higher frequencies in
the high transmission regions (P < 0.001, c
2).
For the 286 isolates tested for N86Y mutation
throughout India, the wild type N86 was observed in
211 (73.77%) isolates. Regional distribution of pfmdr-1
mutation is presented in Table 2. The wild type N86
was significantly more prevalent in the low transmission
regions (n = 120, 94.48%), whereas in high transmission
regions, the wild type (N86) and the mutant (N86Y)
were found in similar proportions, 91 (57.23%) and 68
(42.76%) respectively (P < 0.0001, c
2). The N86Y was
predominantly observed in Assam (76.00%) and Orissa
(51.85%) isolates, whereas wild type N86 was observed
more in isolates from West Bengal (75.00%), Chhattis-
garh (81.25%) and Maharastra (100%).
Distribution of haplotypes
The combination of pfcrt haplotypes and Pfmdr-1 muta-
tions revealed nine haplotypes distributed at variying
rates within different field sites (Table 2). The haplotype
SVMNTS-N occurred in 154 (53.84%) isolates and was
detected in all sites. Its significant occurrence in low
P. falciparum transmission areas 118 (92.91%) isolates is
understandable, as a higher number of SVMNT-S and
N86 was previously observed in these areas. The other
mutant haplotype, SVMNTS-Y was observed in 5.51%
isolates from low P. falciparum transmission areas, while
CVIETS-N and CVMNKA-N each were observed only
one time. In contrast, there was considerable variation
observed in the haplotypes from isolates collected in high
P. falciparum transmission areas i.e. 32 (20.12%) wild
type CVMNKA-N and various mutant types SVMNTS-N
(n = 36, 22.64%), CVIETS-Y (n = 34,21.38%), SVMNTS-
Y (n = 30,18.86%), CVIETS-N (n = 22,13.83%),
CVMNKA-Y (n = 2, 1.25%) and one isolate (0.62%) of
the following haplotypes SVMNTA-N, CVMDTS-Y,
CVMNKS-N.
Distribution of pfcrt and pfmdr-1 mutations in relation to
in vivo CQ efficacy
A total of 240/287 isolates collected from the CQ thera-
peutic efficacy study [25-27] were sequenced for analysis
of pfcrt gene. The mutant K76T was observed irrespec-
tive of treatment outcome. Of the 106 isolates identified
as ACPR (i.e. CQ sensitive isolates), 87 (82.07%) were
found to be mutant K76T, while only 19 (17.92%) con-
tained the wild pfcrt h a p l o t y p eC V M N K A .T h em u t a n t
K76T was observed in the remaining 134 cases classified
as treatment failures (i.e. ETF and LTF). Though the wild
type was observed infrequently across India, it was almost
exclusively detected in high transmission regions (n =
18,94.73%) compared to low transmission region (n =
1,5.26%). The mutant pfcrt haplotype SVMNT-S was pre-
valent in all treatment outcomes, i.e. observed in 71
(66.98%) ACPR, 15 (60.00%) ETF, and 76 (69.72%) LTF
isolates. On the other hand, occurrence of mutant haplo-
type CVIET-S was almost entirely limited to high P. falci-
parum transmission regions and was distributed in all the
clinical outcomes, 15 (14.15%) ACPR, 10 (40.00%) ETF,
a n d3 2( 2 9 . 3 5 % )L T Fi s o l a t e s .O n l yas i n g l ei s o l a t ef r o m
Goa, a low transmission region was identified by the
CVIET-S haplotype. Instances of rare haplotypes were
also observed; CVMDT-S haplotype was observed in one
of the LTF isolate from Jharkhand and SVMNT-A haplo-
type was observed in one of the ACPR isolates from
Orissa. The distribution of pfcrt haplotypes in various
clinical outcomes is presented in Table 3.
In total, 239 isolates underwent successful PCR amplifi-
cation and endonuclease digestion for pfmdr-1 N86Y
mutation. The distribution of the pfmdr-1 mutation
N86Y in the different clinical outcomes is shown in
Table 3. In brief, both the wild type and the mutant
alleles were detected in each of the three different clinical
outcomes; no significant association was found between
wildtype and mutant alleles and the treatment outcome.
The wild type N86 allele was observed in 167 (69.87%) of
Table 1 Description of primer sequences and respective PCR amplification conditions
Amplified region Primer sequence # Amplification condition
pfcrt gene (codons
32-119)
Primary 20: PFCRT 1F 5’CCGTTAATAATAAATACAGGC-3’ PFCRT 1R
5’CTTTAAAAATGGAAGGGTGT 3’ Nested 16: PFK76T
5’-5’GGCTCACGTTTAGGTGGA3’ PRK76T
5’TGAATTTCCCTTTTTATTTCCAAA 3’
94°C 5 min; 94°C 30 sec, 56°C 1 min, 60°C 90 sec (40X), 60°C
3 min. 94°C 5 min; 94°C 30 sec, 52°C 45 sec, 72°C 45 sec
(35X), 72°C 5 min.
pfcrt gene (codons
181-222)
Primary 20: PFCRT 1F 5’CCGTTAATAATAAATACAGGC-3’ PFCRT 1R
5’CTTTAAAAATGGAAGGGTGT 3’ Nested 48: PFA220S
5’CTTATACAATTATCTCGGAGCAG3’ PRA220S
5’ATAATAAAAACAAAGTTTAAGTGT 3’
Same as for above primary 94°C 5 min; 94°C 30 sec, 51°C
45 sec, 72°C 45 sec (35X), 72°C 5 min.
pfmdr-1 gene
(N86Y)
Primary 16: MDR1F 5’ATGGGTAAAGAGCAGAAAGA3’ MDR1R
5’AACGCAAGTAATACATAAAGTCA3’ Nested 47: MDR1FN
5’AGATGGTAACCTCAGTATCA3’ MDR1RN
5’TTACATCCATACAATAACTTG3’
94°C 5 min; 94°C 30 sec, 54°C 45 sec, 72°C 45 sec sec (35Χ),
72°C 5 min. 94°C 5 min; 94°C 30 sec, 49°C 45 sec, 72°C 45 sec
(35X), 72°C 5 min.
# Primer sequences were adapted from Dorsey et al. [20]; Vathsala et al. [16]; Jelinek et al. [28] and Lim et al. [29]
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no. of isolates (%) in high P.falciparum prevalent areas no. of isolates (%) in low P.falciparum prevalent areas
pfcrt haplotype
a Assam Orissa Jharkhand West Bengal Chhattisgarh Maharastra total Gujarat Goa Tamil Nadu Rajasthan Uttar Pradesh total
CVMNK-A 0 11(20.37) 7(20.58) 0 11(68.75) 5(35.72) 34(21.25) 0 0 0 1(3.85) 0 1(0.78)
CVIET-S 15(57.69) 17(31.48) 20(58.82) 4(25) 0 0 56 (35) 0 1(3.85) 0 0 0 1(0.78)
SVMNT-S 11(42.30) 25(46.29) 6(17.64) 12(75) 4(25) 9(64.28) 67(41.87) 33(100) 25(96.15) 25(100) 25(96.25) 17(100) 125(98.42)
CVMDT-S 0 0 1(2.94) 0 0 0 1(0.62) 0 0 0 0 0 0
CVMNK-S 0 0 0 0 1(6.25) 0 1(0.62) 0 0 0 0 0 0
SVMNT-A 0 1(1.85) 0 0 0 0 1(0.62) 0 0 0 0 0 0
pfmdr mutation
b
N86 wt 6(24) 28(51.85) 18(52.94) 12(75) 13(81.25) 14(100) 91(57.23) 32(96.96) 26(100) 24(96) 21(80.76) 17(100) 120(94.48)
N86Y mt 19(76) 26(48.14) 16(47.05) 4(25) 3(18.75) 0 68(42.76) 1(3.03) 1(4) 5(19.23) 7(5.51)
Combined genotype
a
CVIETS -N 3(12) 8(14.81) 11(32.35) 0 0 0 22(13.83) 0 1(3.85) 0 0 0 1(0.78)
CVIETS -Y 12(48) 9(16.66) 9(26.47) 4(25) 0 0 34(21.38) 0 0 0 0 0 0
SVMNTA -N 0 1(1.8) 0 0 0 0 1(0.62) 0 0 0 0 0 0
SVMNTS -N 3(12) 10(18.51) 1(2.9) 12(75) 1(6.25) 9(64.28) 36(22.64) 32(96.96) 25(96.15) 24(96) 20(76.92) 17(100) 118(92.91)
SVMNTS-Y 7(28) 15(27.77) 5(14.7) 0 3(18.75) 0 30(18.86) 1(3.03) 0 1(4) 5(19.23) 0 7(5.51)
CVMNKA-N 0 9(16.66) 7(20.58) 0 11(68.75) 5(35.71) 32(20.12) 0 0 0 1(3.85) 0 1(0.78)
CVMNKA-Y 0 2(3.7) 0 0 0 0 2(1.25) 0 0 0 0 0 0
CVMDTS -Y 0 0 1(2.9) 0 0 0 1(0.62) 0 0 0 0 0 0
CVMNKS -N 0 0 0 0 1(6.25) 0 1(0.62) 0 0 0 0 0 0
aMutated amino acid is underlined,
b wt Wild type, mt Mutant type
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0Table 3 The distribution of mutations in different clinical responses
CQ RESPONSE ASSAM
a ORISSA JHARKHAND W.BENGAL GUJARAT GOA TAMIL NADU RAJASTHAN TOTAL
ACPR pfcrt haplotype
b
CVMNK-A 0 11(45.83) 7(41.17) 0 0 0 0 1(3.85) 19(17.92)
CVIET-S 5(41.66) 3(12.50) 6(35.29) 1(14.28) 0 0 0 0 15(14.15)
SVMNT-A 0 1(4.16) 0 0 0 0 0 0 1(0.94)
SVMNT-S 7(58.33) 9(37.50) 4(23.52) 6(85.71) 6(100) 8(100) 6(100) 25(96.25) 71(66.98)
pfmdr mutation
c
N86 wt 1(9.09) 18(75.00) 13(76.47) 6(85.71) 6(100) 8(100) 6(100) 21(80.76) 79(75.23)
N86Y mt 10(90.90) 6(25.00) 4(23.52) 1(14.28) 0 0 0 5(19.23) 26(24.76)
Combined genotype
b
CVMNKA N 0 9(37.50) 7(41.17) 0 0 0 0 1(3.85) 17(16.19)
CVMNKA Y 0 2(8.33) 0 0 0 0 0 0 2(1.90)
SVMNTS N 0 6(25.00) 1(5.88) 6(85.71) 6(100) 8(100) 6(100) 20(76.92) 53(50.47)
SVMNTSY 6(54.54) 3(12.50) 3(17.64) 0 0 0 0 5(19.23) 17(16.19)
SVMNTA N 0 1(4.16) 0 0 0 0 0 0 1(0.95)
CVIETS N 1(9.09) 2(8.33) 5(29.41) 0 0 0 0 0 8(7.61)
CVIETSY 4(36.36) 1(4.16) 1(5.88) 1(14.28) 0 0 0 0 7(6.66)
ETF pfcrt haplotype
CVIET-S 2(40) 4(66.66) 2(100) 1(50) 0 1(11.11) 0 0 10(40.00)
SVMNT-S 3(60) 2(33.33) 0 1(50) 1(100) 8(88.88) 0 0 15(60.00)
pfmdr mutation
N86 wt 4(80) 2(33.33) 1(50) 1(50) 1(100) 9(100) 0 0 18(72.00)
N86Y mt 1(20) 4(66.66) 1(50) 1(50) 0 0 0 0 7(28.00)
combined genotype
SVMNTS N 2(40) 1(16.66) 0 1(50) 1(100) 8(88.88) 0 0 13(52.00)
SVMNTSY 1(20) 1(16.66) 0 0 0 0 0 0 2(8.00)
CVIETS N 2(40) 1(16.66) 1(50) 0 0 1(11.11) 0 0 5(20.00)
CVIETSY 0 3(50.00) 1(50) 1(50) 0 0 0 0 5(20.00)
LTF pfcrt haplotype
CVIET-S 8(88.88) 10(41.66) 12(80) 2(28.57) 0 0 0 0 32(29.35)
SVMNT-S 1(11.11) 14(58.33) 2(13.33) 5(71.42) 26(100) 9(100) 19(100) 0 76(69.72)
CVMDT-S 0 0 1(6.66) 0 0 0 0 0 1(0.91)
pfmdr mutation
N86 wt 1(11.11) 8(33.33) 4(26.66) 5(71.42) 25(96.15) 9(100) 18(94.73) 0 70(64.22)
N86Y mt 8(88.88) 16(66.66) 11(73.33) 2(28.57) 1(3.84) 0 1(5.26) 0 39(35.77)
combined genotype
SVMNTS N 1(11.11) 3(12.50) 0 5(71.42) 25(96.15) 9(100) 18(94.73) 0 61(55.96)
SVMNTSY 0 11(45.83) 2(13.33) 0 1(3.84) 0 1(5.26) 0 15(13.76)
CVIETS N 0 5(20.83) 5(33.33) 0 0 0 0 0 10(9.17)
CVIETSY 8(88.88) 5(20.83) 7(46.66) 2(28.57) 0 0 0 0 22(20.18)
CVMDTSY 0 0 1(6.66) 0 0 0 0 0 1(0.91)
a Respective percentage values in brackets,
b Mutated amino acid is underlined,
c wt Wild type, mt Mutant type
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0the 239 isolates and distributed accordingly; 79 (75.23%)
ACPR, 18 (72.00%) ETF, and 70 (64.22%) as LTF. Simi-
larly mutant N86Y allele was found in 26 (24.76%) of iso-
lates classified as ACPR, 7(28.00%) as ETF and 39
(35.77%) as LTF. The combination of pfcrt haplotypes
and Pfmdr-1 mutations revealed again, that SVMNTS-N
prevail in all the category of clinical outcome also; 53
(50.47%) isolates in ACPR, 13 (52.00%) isolates in ETF,
61 (55.96%) isolates in LTF.
Discussion
In this study, the distribution of pfcrt haplotypes and the
pfmdr-1 mutation (N86Y) has been described across 11
sites in India and evaluated for a correlation between the
prevalence of mutations and the clinical outcome of CQ
treatment. The distribution of pfcrt haplotypes in associa-
tion with the clinical outcome of treatment supports that
the K76T mutation is the most predictive marker of CQR
in the field [3,4]. The wild type CVMNK-A haplotype was
found to be exclusively restricted to the ACPR outcome
group (P < 0.001, Fisher’s exact test). However, the wild
type CVMNK-A haplotype was not the predominant hap-
lotype in the ACPR outcome group; in fact, 82.07% of the
isolates identified as ACPR carried a mutant haplotype.
From this data, it is proposed that the typing of molecular
markers for CQ resistance may infer an intrinsic charac-
teristic of the parasite, but may not necessarily be suffi-
cient to predict treatment outcome. Treatment outcome
may depend on other factors, such as host-parasite or
host-drug interaction [30]. Exposure-related host immu-
nity may play an essential role in naturally clearing the
parasite infection, irrespective of their response to any
drug. Some studies have shown that host immunity is also
associated with clearance of resistant genotypes [20,31].
Additionally, the mutant haplotype SVMNT-S (charac-
teristic of South American or PNG CQR isolates) was
observed in all sites across India, regardless of the clinical
outcome. Observation made in this study support earlier
reports regarding the prevalence of SVMNT-S haplotype
among the CQR isolates in India [16-18]. Perhaps the
most striking observation observation in the study is that
the SVMNT-S haplotype is endemic across all the sites of
low P. falciparum malaria transmission, while in high
transmission regions there are multiple mutant pfcrt hap-
lotypes observed. These different haplotype combinations
observed in regions of high transmission might be indica-
tive of random mating patterns among parasites within
these regions, which could be influenced by the local rate
of malaria transmission. The role of transmission in the
evolution and spread of drug resistance remains a matter
of debate, as it has been hypothesized by some that low
transmission may decrease circulating drug resistance,
while others hypothesize that low transmission may
increase drug resistance [32,33]. These studies signify the
effect of transmission on altering the spread of drug resis-
tance. In this study, the distribution of mutations hints
that the spread of CQR might be under the influence of
the transmission intensity and the distribution of anti-
malarial drugs. Though complexity of infection (minimum
number of clones within an infection) was not character-
ized in this study, it is common to observe a higher pro-
portion of multiclonal infections in regions of high
transmission, compared to regions of low transmission
[34-37]. The ubiquitous nature of mutant SVMNT-S pfcrt
haplotype in the low transmission regions in this study
may be a direct consequence of higher inbreeding poten-
tial of resistant parasites due to low frequencies of com-
plex and multiclonal infections. An inbreeding population,
consisting mostly of resistant genotypes could spread para-
site drug resistance expeditiously [32,38]. This expansion
of mutant SVMNT-S is likely to be enhanced by extensive
exposure of CQ in these P. vivax predominated areas, as
chloroquine is the first-line drug for vivax malaria in India.
A similar expansions hasbeen observed for the pfmdr-1
wild type N86 in these P. vivax prevalent areas. Again
inbreeding might be the cause for this expansion in low
transmission regions.
The significant presence of wild type CVMNK-A in high
P. falciparum prevalent areas (Orissa, Jharkhand, Chhattis-
garh) supports earlier reports on acquisition of immunity
in high endemic areas, which creates a natural ecological
refuge for drug sensitive parasites [31,39]. This could pos-
sibly explain the occurrence of the wild type haplotype in
high P. falciparum prevalent areas. Further, appearance of
the mutant haplotype CVIET-S(characteristic of Southeast
Asian CQR parasite) is expected to be observed within
eastern and northeastern parts of the country, because this
region shares international borders with Bangladesh,
Nepal, Bhutan, Myanmar and China and harbour migrant
populations. The CVIET-S haplotype might be indicative
of high drug pressure in regions of high transmission, as
earlier observations have shown that the CVIET-S haplo-
type have higher IC50 for CQ [17,40]. Similarly, the preva-
lence of pfmdr-1 mutant N86Y found in these areas may
be involved in modulating the CQ response in Indian iso-
lates. Isolates with the two loci mutation (pfcrt-pfmdr-1)
were limited to high P. falciparum transmission regions,
where N86Y appeared with both the pfcrt mutant haplo-
type SVMNT-S and CVIET-S. These two mutant haplo-
types were observed in high numbers at Assam, Orissa,
and Jharkhand, whereas Chhattisgarh shows a higher fre-
quency of the wild type for both loci. This study has not
evaluated IC50 values for particular pfcrt haplotypes, but
the observed prevalence of the mutant SVMNT-S, even in
the high transmission regions may be an indication of
increased transmission potential of these resistant para-
sites [40]. The use of amodiaquine as monotherapy or in
combination has been associated with the prevalence of
Mallick et al. Malaria Journal 2012, 11:16
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In India, amodiaquine was used as presumptive anti-
malarial drug for CQR parasite in 1980’s in these high
transmission regions [43-45] and may be a possible expla-
nation for the introduction and spread of SVMNT-S hap-
lotype. On the other hand, a recent investigation from
central India, using multilocus microsatellites, compared
the evolutionary proximity of Indian SVMNT-S haplotype
with other parts of the world and reveals its close relation
to the SVMNT genotype found in PNG [19]. So, overall
the spread of SVMNT is intriguing and require further
investigation about its origin and spread in India.
The observed prevalence of the wild type pfmdr-1 N86
allele could be a cause for concern, because a recent study
reported that the selection of this allele is associated with
resistance to one of the artemisinin-based combination
therapy (ACT-Coartem
®)d e s s e m i n a t e di nE a s tA f r i c a
[46]. This allele has also been associated with a decreased
sensitivity to lumefantrine in vitro [47,48]. Furthermore,
the significant prevalence (P < 0.001) of wild type N86 in
low P. falciparum prevalent areas, seems to be fixed and
may result in an easy escape for parasites exposed to this
drug combination. Ultimately, this fixation could lead to
the rapid spread of resistant parasites. However, a recent
investigation of therapeutic efficacy of Coartem
® in the
high P. falciparum transmission regions marks successful
outcome without any selection of N86 [49].
Conclusions
This studyobserved a striking pattern in fixation of
mutant SVMNT pfcrt haplotype at low P. falciparum
prevalent areas, which raise concerns about faster spread
of anti-malarial resistance in these areas. The absence of
wild type pfcrt haplotype in most part of the country
may lead to a situation where no reversal of wild type
would happen even in the absence of CQ pressure. This
study leads towards understanding the role of malaria
transmission intensity in spread of anti-malarial resistant
parasite in India, and it will be useful in designing anti-
malarial treatment policy.
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